Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It improves glycaemic control by enhancing insulin secretion in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to healthcare providers across multiple regions. Mifoglame is manufactured under GMP conditions and is available for bulk and unit‑dose distribution.

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: lowers HbA1c and fasting glucose when combined with diet and exercise. Adjunct therapy: used alongside metformin or other antidiabetics to achieve target glucose levels. Monotherapy: may be prescribed alone in patients intolerant to other agents.

Sitagliptin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient pain in the head region. - Upper respiratory tract infection: symptoms of common cold. - Gastrointestinal upset: nausea, diarrhea or abdominal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angio‑edema, Stevens‑Johnson syndrome or anaphylaxis. - Arthralgia: intense joint pain that may be disabling.

When prescribing or dispensing sitagliptin, consider the following precautions.

Renal function: dose adjustment may be required in patients with impaired renal function. Hypersensitivity: discontinue if signs of allergic reaction appear. Pancreatitis: monitor for persistent abdominal pain. Heart failure: use with caution in patients with a history of heart failure. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Sitagliptin can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce sitagliptin efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood glucose control. - ACE inhibitors/ARBs: monitor renal function when combined. - Warfarin: occasional changes in INR reported; monitor coagulation parameters.